An observational study in Transgenderism, Gender Dysphoria and Insulin Sensitivity, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 13 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-06-10.
Sponsored by University of Colorado, Denver · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Gender Dysphoria with a site in United States — 11 open to participants now, 13 under way, 3 of them phase 3. Gender Dysphoria · United States.
Among the 31 studies in Gender Dysphoria with a site in United States, this one is the 5th largest by planned enrollment of the 16 observational ones that give a count, is one of 3 that started in 2021, is one of 16 observational ones, reaches primary completion later than 2 of the 12 other live ones, and was the 12th registered.
85 studies on the registry are indexed under Gender Dysphoria; 38 are open to participants now.
Browse Gender Dysphoria studies →11 of the 31 studies in Gender Dysphoria with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18–45 · Healthy volunteers
University Hospitals Cleveland Medical Center · Sites in United States
Ages 19–99 · Men only
Women and Infants Hospital of Rhode Island · Sites in United States
Ages 18+ · Women only
University of Virginia · Sites in United States
Ages 18+ · Women only
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Gender Dysphoria studies recruiting now, 15 (48%) set no upper age limit and 10 (32%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 13 Years to 16 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 3 · Phase 4 4
First in 2017; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 100 across 52 observational studies indexed under Gender Dysphoria.
Median enrollment 50 across the 15 interventional studies, 46 across the 16 observational. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 31 has an industry lead sponsor. The 10 most frequent:
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
University of Colorado, Denver has 3 studies filed under Gender Dysphoria — fewer than ten, so there is no comparison to draw.
2 of the studies in Gender Dysphoria with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07412509University of ChicagoCan 3D Modeling Enhance Patient Understanding, Education, and Surgical Outcomes in Gender Affirming Peritoneal Vaginoplasty? | 2027-03 |
| NCT07286123University Hospitals Cleveland Medical CenterGender Affirming Vaginoplasty With Tubularized Augmented Peritoneal Cap (TAPCap) Utilizing Fish Skin Xenograft (Kerecis™) | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Gender Dysphoria with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the effect of estradiol with or without a prior gonadotropin releasing hormone analogue on insulin sensitivity and vascular function in transgender females compared to cisgender controls.
85 studies on the registry are indexed under Gender Dysphoria; 38 are open to participants now.
This study's planned enrollment of 90 is close to the median of 100 across 52 observational studies indexed under Gender Dysphoria.
Browse Gender Dysphoria studies →University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
Compared within Gender Dysphoria, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Transsexualism. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Transgender and cisgender adolescents
Inclusion Criteria (transgender females):
Inclusion Criteria (cisgender males and females):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Insulin sensitivity
Time frame: Change from baseline to 12 months
Brachial artery flow mediated dilation
Time frame: Change from baseline to 12 months
Large artery stiffness
Carotid artery ultrasound
Time frame: Change from baseline to 12 months
Cerebrovascular function
Middle cerebral artery blood flow
Time frame: Change from baseline to 12 months
VO2 peak
Time frame: Change from baseline to 12 months
Fat mass
DXA
Time frame: Change from baseline to 12 months
Fat-free mass
DXA
Time frame: Change from baseline to 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2021 (actual). Primary completion is estimated for Jul 2026, 65 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →